Kymera Therapeutics Inc, a biotechnology company, has signed a multi-program strategic collaboration with Sanofi (NASDAQ: SNY), a France-based pharmaceutical company, for developing and commercialising first-in-class protein degrader therapies targeting IRAK4, a key protein involved in inflammation, in patients with immune-inflammatory diseases, it was reported on Thursday.
Both firms will also collaborate on a second earlier stage program.
According to the terms of the deal, Sanofi will make an upfront payment of USD150m in cash to Kymera for global rights to develop IRAK4 protein degraders for inflammation and immunology indications, and a second earlier stage undisclosed program. Kymera is to advance the IRAK4 program via Phase one clinical trials and Sanofi will assume clinical development and commercialisation responsibilities thereafter. Sanofi is to lead all clinical development activities for the second program, while Kymera will have the option to participate in the development of both programs in the United States during clinical development. Kymera is to retain global rights to its IRAK4 program in oncology indications.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval